NeoGenomics has now redeemed 100 percent of the $110 million preferred stock issues in conjunction with the Clarient acquisition, at a cost of $105 million.
The company immediately borrowed $255 million to pay part of the $680 million price tag for Alere's MeterPro cardiovascular and toxicology business and its BNP assay business.
The company amended and restated an existing senior revolving credit facility in the principal amount of $1.0 billion with the ability to increase it by up to $350 million.
Castle will use the proceeds to accelerate marketing and new product development related to its molecular prognostic tests for patients with underserved cancers.